TGen appoints Dr. Aleksandar Sekulic as Physician-in-Chief

The Translational Genomics Research Institute (TGen), part of City of Hope, today announced the appointment of Aleksandar Sekulic, M.D., Ph.D., a distinguished physician-scientist known for his work in skin cancer treatment and clinical research, as Physician-in-Chief. Dr. Sekulic specializes in immunotherapy and targeted therapies for a range of skin cancers, from melanoma to rare types of cutaneous lymphoma and epidermal neoplasms. His patient care approach integrates advanced treatments with a focus on individual needs, ensuring comprehensive, whole-person care.Continue reading

Applications for the Banner-ASU Neuroscience Scholars Program are open until March 2 2025

NIH Announces New Indirect Cost Rates of 15%

NIH announced on February 7, 2025 that effective Monday, February 10, 2025,  “In accordance with 45 CFR 75 and its accompanying appendices, this Guidance implements and makes publicly available NIH’s updated policy deviating from the negotiated indirect cost rate for new grant awards and existing grant awards, effective as of the date of this Guidance’s issuance. Pursuant to this Supplemental Guidance, there will be a standard indirect rate of 15% across all NIH grants for indirect costs in lieu of a separately negotiated rate for indirect costs in every grant.”

Read Notice Number NOT-OD-25-068 for more information.Continue reading